MedPage -- After reviewing results of an aborted European study involving tinzaparin (Innohep), a low molecular weight heparin product, the FDA said the drug’s label should reflect increased risks for patients 70 and older.
MedPage -- After reviewing results of an aborted European study involving tinzaparin (Innohep), a low molecular weight heparin product, the FDA said the drug’s label should reflect increased risks for patients 70 and older.
